A
ATXS

AJOVista’s Astria Therapeutics ATXS Stock Holding History

AJOVista’s Portfolio ATXS Stock Details ATXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-6,636
Closed -$51K – 106
2023
Q4 		$51K Buy
+6,636
New +$36.7K 0.06% 293

Other funds holding ATXS

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AJOVista's ATXS Position: Q1 2024 in Review

AJOVista sold out of Astria Therapeutics (ATXS) in Q1 2024, closing a stake of 6,636 shares — an estimated $51K sold.

AJOVista first reported a position in ATXS in Q4 2023 and held it in 1 quarter. The position peaked at $51K in Q4 2023. 102 funds tracked by Wall St. Rank hold ATXS as of Q1 2024.

  • AJOVista reported no remaining Astria Therapeutics position as of Q1 2024 after selling out during the quarter.
  • AJOVista sold 6,636 Astria Therapeutics shares in Q1 2024, an estimated $51K.
  • AJOVista first reported a position in Astria Therapeutics in Q4 2023 and held it in 1 quarter.
  • AJOVista's Astria Therapeutics position peaked at $51K in Q4 2023.
  • 102 funds tracked by Wall St. Rank held Astria Therapeutics as of Q1 2024.

Based on AJOVista's 13F filing for Q1 2024, filed 10 May 2024.